Disparities in outcomes of pancreatic cancer hospitalizations: A ten-year trend study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer. This is an ASCO Meeting ...

The Gastrointestinal Tumor Study Group study and the Mayo Clinic study helped define chemoradiation with 5FU as the standard of care in locally advanced pancreatic cancer. Currently, typical ...

Historically, high-dose radiation has been considered beneficial for improving survival rates in patients with unresectable pancreatic cancer. Yet, the application has often been limited due to ...

Approximately 30% of pancreatic cancer patients present with locally unresectable disease with no evidence of distant metastases. Local control in this patient population can provide effective ...

The San Francisco biotech confirmed that neither the PanCAN Precision Promise study in metastatic pancreatic cancer nor the LAPIS trial in patients with locally advanced, unresectable pancreatic ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

including safety and feasibility studies treating patients with pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across ... for recurrent unresectable or metastatic head and neck squamous cell carcinoma ...

including safety and feasibility studies treating patients with pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other ...